NASDAQ: WGRXWellgistics Health Inc Stock
$3.39-0.31 (-8.38%)
Updated Jun 18, 2026
WGRX Price
$3.39
Fair Value Price
N/A
Market Cap
$94.20k
52 Week Low
$3.04
52 Week High
$97.50
P/E
-0.08x
P/B
-0.01x
P/S
0.72x
PEG
N/A
Dividend Yield
N/A
Revenue
$14.03M
Earnings
-$76.59M
Gross Margin
-49.5%
Operating Margin
-506.12%
Profit Margin
-545.7%
Debt to Equity
-3
Operating Cash Flow
-$13M
Beta
1.29
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
WGRX Overview
Wellgistics Health, Inc. functions as a primary wholesaler and distributor of pharmaceutical products throughout the United States, catering to both drug manufacturers and independent retail pharmacies. Its extensive product catalog includes a variety of generic and brand-name pharmaceuticals, alongside over-the-counter healthcare and consumer merchandise. The company also delivers a suite of third-party logistics (3PL) services, encompassing warehousing, inventory control, pick-and-pack operations, and shipping solutions, specifically designed for small to mid-sized pharmaceutical producers. Furthermore, Wellgistics manages the DelivMeds platform, an integrated pharmaceutical hub that streamlines prescription transfers and offers essential backend clinical concierge support to its network of independent pharmacies. It also runs a specialized retail community service. Established in 2022 and headquartered in Tampa, Florida, the organization adopted its current name, Wellgistics Health, Inc., in October 2024, having previously operated as Danam Health, Inc.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine WGRX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical Retailer
Industry Rating
D
WGRX
Ranked#4 of 4
Ranked#4 of 4
Be the first to know about important WGRX news, forecast changes, insider trades & much more!
WGRX News
Overview
Due Diligence Score
–
Industry Average (19)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how WGRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
WGRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
WGRX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
WGRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more WGRX due diligence checks available for Premium users.
Valuation
WGRX fair value
Fair Value of WGRX stock based on Discounted Cash Flow (DCF)
Price
$3.39
Fair Value
$0.08
Overvalued by
4,117.81%
WGRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
WGRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.08x
Industry
-3.93x
Market
9.47x
WGRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.01x
Industry
43.76x
WGRX's financial health
Profit margin
Revenue
$1.6M
Net Income
-$7.7M
Profit Margin
-496.5%
WGRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
WGRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$30.1M
Liabilities
$45.2M
Debt to equity
-3
WGRX's short-term liabilities ($32.20M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
WGRX's long-term liabilities ($12.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
WGRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
WGRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.4M
Investing
-$205.1k
Financing
$3.6M
WGRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
WGRX vs Pharmaceutical Retailer Stocks
Wellgistics Health Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.